1. Australia Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Nexalis Therapeutics Limited

Nexalis Therapeutics Limited

AASX:NX1
0.01
AUD
-0.01
(-40.00%)
-0.01EPS
5.74MMarket Cap
Nexalis Therapeutics Limited
ASX:NX1
(Australian Securities Exchange)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AUD
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.03
-0.02
-0.03
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.07
0.03
0.01
0.01
0.02
0.01
- -
- -
- -
Book Value per Share
- -
0.06
0.02
0.01
0.01
0.02
0.01
- -
- -
- -
Tangible Book Value per Share
27
78
78
80
100
169
174
191
215
216
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-561.04
-566.64
-4,264.58
-9,676.98
-672.98
-7,879.44
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-2
-2
-2
-1
-1
-2
-1
-1
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-424.69
-542.2
-4,877.06
-8,054.01
-664.15
-7,647.6
- -
- -
- -
Profit Margin (%)
- -
4
2
- -
2
3
2
1
- -
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
5
3
- -
2
3
2
1
- -
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-48.24
-148.65
-98.18
-51.72
-82.36
-111.3
- -
- -
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
319.85%
1,736.91%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
14.86%
33.85%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.01
2025
- -
- -
-0.01

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Nexalis Therapeutics Ltd. engages in the development and commercialization of medical technologies. Its products include BodyTel Systems and Seng Vital Cannabis Vaporisers. The company was founded on April 13, 2016 and is headquartered in Melbourne, Australia.